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Aim To analyze the incidence and characteristics of ve-
nous thromboembolism (VTE) in Croatia.
Methods The Croatian Cooperative Group for Hematolog-
ic Diseases conducted an observational non-intervention-
al study in 2011. Medical records of patients with newly di-
agnosed VTE hospitalized in general hospitals in 4 Croatian 
counties (Šibenik-Knin, Koprivnica-Križevci, Brod-Posavina, 
and Varaždin County) were reviewed. According to 2011 
Census, the population of these counties comprises 13.1% 
of the Croatian population.
Results There were 663 patients with VTE; 408 (61.54%) 
had deep vein thrombosis, 219 (33.03%) had pulmonary 
embolism, and 36 (5.43%) had both conditions. Median 
age was 71 years, 290 (43.7%) were men and 373 (56.3%) 
women. Secondary VTE was found in 57.3% of partici-
pants, idiopathic VTE in 42.7%, and recurrent VTE in 11.9%. 
There were no differences between patients with second-
ary VTE and patients with idiopathic VTE in disease recur-
rence and sex. The most frequent causes of secondary VTE 
were cancer (40.8%), and trauma, surgery, and immobili-
zation (38.2%), while 42.9% patients with secondary VTE 
had ≥2 causes. There were 8.9% patients ≤45 years; 3.3% 
with idiopathic or recurrent VTE. Seventy patients (10.6%) 
died, more of whom had secondary (81.4%) than idiopath-
ic (18.6%) VTE (P < 0.001), and in 50.0% VTE was the main 
cause of death. Estimated incidence of VTE in Croatia was 
1.185 per 1000 people.
Conclusion Characteristics of VTE in Croatia are similar 
to those reported in large international studies. Improved 
thromboprophylaxis during the presence of risk factors for 
secondary VTE might substantially lower the VTE burden.
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Venous thromboembolism (VTE), including deep venous 
thrombosis (DVT) and pulmonary embolism (PE), is a 
major health problem in the world, associated with sig-
nificant morbidity and mortality (1-9). Incidence rates for 
VTE mostly vary from 1 to 2 in 1000 individuals per year 
(1-5,7,9). PE, the most serious manifestation of VTE, has 
a mortality rate of more than 15% in the first 3 months 
after diagnosis, with short-term survival of less than 60% 
(10,11). Cohen et al estimated that the number of VTE-re-
lated deaths across the European Union (EU) was 543 454 
per year, which was more than double the number of 
combined deaths in EU due to AIDS, breast and prostate 
cancer, and traffic accidents (8).
VTE in survivors is associated with several chronic conse-
quences of the disease that can severely impair the patients’ 
quality of life, including post-thrombotic syndrome (PTS) 
and pulmonary hypertension (PH), as well as recurrent VTE. 
PTS affects at least one-third of patients after DVT (8,12-
15) and PH affects 4%-5% of patients after PE (8,16,17). VTE 
has significant incidence of recurrence: 10.1% at 6 months, 
12.9% after 1 year, and 30.4% after 10 years (18).
Total VTE-related costs to health care system are enormous. 
For example, the total cost of VTE to the UK National Health 
Service in 1993 was £235-£257 million (€349-€382 million), 
and the combined direct and indirect costs in 2004/2005 
were approximately £640 million (€950 million), and are 
even higher when PTS is taken into account (8,19,20).
VTE is a multifactorial disease, resulting from a complex in-
teraction of genetic and acquired factors. Although some 
studies estimated that genetics was related to up to 60% 
of the risk of VTE (including FV Leiden and prothrombin 
G20210A mutations, deficiencies of protein C, S and an-
tithrombin, and elevations of some procoagulant factors) 
(21), there is also a large number of acquired risk factors for 
VTE such as immobilization, surgery, trauma, cancer, preg-
nancy and puerperium, oral contraceptives, autoimmune 
diseases, and other disorders (1-8,21).
In spite of the importance of VTE, there is not enough data 
on its incidence and characteristics in transitional coun-
tries. Also, although several studies analyzed the epidemi-
ology of VTE in different study settings (1-9), there is still not 
much information on conditions present at the diagnosis 
of thrombosis, comparing idiopathic and secondary (pro-
voked) VTE. Therefore, the Croatian Cooperative Group for 
Hematologic Diseases (CROHEM) analyzed the incidence 
and characteristics of idiopathic and secondary newly di-
agnosed VTE in Croatia in 2011, the year of the most recent 
national population census.
MateRiaL aND MetHoDS
CROHEM conducted an observational non interventional 
study of patients with newly diagnosed VTE hospitalized in 
major general hospitals in four Croatian counties: Šibenik-
Knin (General Hospital Šibenik, Šibenik, and General Hospital 
“Hrvatski Ponos,” Knin), Koprivnica-Križevci (General Hospital 
“Dr. Tomislav Bardek,” Koprivnica), Brod-Posavina (Gener-
al Hospital “Dr. Josip Benčević” in Slavonski Brod and Nova 
Gradiška), and Varaždin County (General Hospital Varaždin) 
from January 1 until December 31 2011. The study was ap-
proved by the medical ethics committee of each hospital.
From patients’ hospital records we collected information 
on age, sex, date of incident, category of VTE (DVT, PE, or 
both); characteristics of VTE (idiopathic or secondary, first 
or recurrent); and comorbidities. Diagnosis and treatment 
of VTE was performed in each hospital according to stan-
dard clinical practice and local policy and was not part of 
this study analysis.
VTE was classified as idiopathic or secondary. It was clas-
sified as secondary VTE (DVT, PE, or both) if it was associ-
ated with major trauma, surgery, or marked immobility; 
sepsis; cancer active within 6 months of VTE event; im-
planted venous catheter; pregnancy or puerperium at the 
time of VTE; usage of some prothrombotic medicaments 
at the time of VTE (ie, oral contraceptives, hormonal re-
placement therapy); autoimmune or other prothrombotic 
diseases (ie, antiphospholipid syndrome, systemic lupus 
erythematosus, inflammatory bowel disease, neurologic 
diseases with paralysis); or if occurred after >6 h long dis-
tance airplane flight. VTE was classified as idiopathic when 
none of these precipitating factors were registered. VTE 
was also classified as the first or recurrent. VTE was con-
sidered recurrent if prior VTE events were registered in the 
medical record. Patients who died during hospitalization 
when VTE was diagnosed were recorded and the main 
cause of death was categorized as VTE-related or related 
to some other main cause.
According to the 2011 Population Census, the Repub-
lic of Croatia had 4 284 889 inhabitants (48.2% men), and 
the population was on average 41.7 years old (men 39.9, 
women 43.4 years), which places it among the oldest na-
tions in Europe (22). Of the counties included in this 
study, one was from the southern (Dalmatian) part 
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of Croatia (Šibenik-Knin County, with 109 375 inhabitants, 
53 596 [49%] men, average age 44.1 years), two were from 
the northern part of Croatia (Varaždin County, with 175 951 
inhabitants, 85 645 [48.7%] men, average age 41.2 years, 
and Koprivnica-Križevci County, with 115 584 inhabitants, 
55 964 [48.4%] men, average age 41.6 years), and one 
from the eastern (Slavonian) part of Croatia (Brod-Posavi-
na County, with 158 574 inhabitants, 77 115 [48.6%] men, 
average age 40.6 years). These 4 counties have 559 485 in-
habitants (272 320 (48.7%) men), which represents 13.1% 
of Croatian population (22).
Statistical analysis
Categorical data are presented with absolute (N) and rela-
tive (%) frequencies and compared using χ2-test, and nu-
merical data are presented with median and range values 
and compared using t test. Only P < 0.050 was considered 
significant. Annual incidence per 1000 inhabitants was cal-
culated using the number of recorded new VTE cases as 
the numerator and the population at risk in the 4 coun-
ties as the denominator, according to the 2011 Census (22). 
Data were analyzed using MedCalc program (MedCalc Sta-
tistical Software version 15.6.1, MedCalc Software bvba, 
Ostend, Belgium).
ReSuLtS
In 2011, there were 663 new cases of VTE in 4 Croatian coun-
ties: 408 (61.54%) of them had DVT, 219 (33.03%) had PE, 
and 36 (5.43%) had both conditions (Table 1). The majority 
of patients were elderly people (median age 71 years, range 
13-97 years), and there were more women (N = 373, 56.3%) 
(Table 1). Female patients were significantly older (median 
74, range 21-97 years) than male (median 65, range 13-90 
years; P < 0.001). Patients with PE or with both PE and DVT 
were significantly older than patients with DVT alone (me-
dian and range; 74 [21-97] vs 69 [13-92] years, P = 0.006).
Recurrent VTE was diagnosed in 79 (11.9%) patients (Ta-
ble 2). There were more patients with secondary (N = 380, 
57.3%) than with idiopathic VTE (N = 283, 42.7%) (Tables 
2-3). Patients with idiopathic VTE were significantly older 
than those with secondary VTE (median and range; 74 [26-
92] vs 69 [13-97] years, P = 0.001). There were no differences 
between patients with secondary and patients with idio-
pathic VTE in disease recurrence and sex.
The most frequent causes of secondary VTE were cancer 
(40.8% of secondary VTE) and trauma, surgery, and immo-
bilization (38.2% of secondary VTE). Other causes included 
sepsis, other diseases (eg, autoimmune diseases, inflam-
matory bowel diseases, neurological diseases with paral-
ysis), central venous catheter, drugs, pregnancy and pu-
erperium, and >6 h airplane flight. Patients with trauma, 
surgery, or immobilization were significantly younger than 
other patients with VTE (median and range; 67 [13-90] vs 
72 [21-97] years, P = 0.003). Many of the 380 cases of sec-
ondary VTE (N = 163, 42.9% of secondary VTE) had more 
than one underlying condition (Table 3).
taBLe 1. Diagnosis, sex, and age of patients with newly diagnosed venous thromboembolism (Vte) in 4 Croatian counties in 2011*
Diagnosis Vte N (% Vte) Sex age in years
County total Vte (N) DVt Pe DVt+Pe male N (%) female N (%) (median, range)
Šibenik-Knin 151  99 (65.56)  43 (28.46)  9 (5.96)  64 (42.4)  87 (57.62) 72 (13-92)
Koprivnica-Križevci  87  54 (62.07)  26 (29.89)  7 (8.05)  39 (44.8)  48 (55.2) 69 (26-90)
Varaždin 298 159 (53.36) 128 (42.95) 11 (3.69) 125 (41.9) 173 (58.1) 73 (21-97)
Brod-Posavina 127  96 (75.59)  22 (17.32)  9 (7.09)  62 (48.82)  65 (51.2) 67 (33-88)
Total 663 408 (61.54) 219 (33.03) 36 (5.43) 290 (43.7) 373 (56.3) 71 (13-97)
*Pe – pulmonary embolism; DVt – deep venous thrombosis.
taBLe 2. idiopathic and recurrent venous thromboembolism (Vte), death, and cause of death of patients with newly diagnosed Vte 
in 4 Croatian counties in 2011
Reason of death N (% of death)
County idiopathic N (%) Reccurent N (%) Death N (% Vte) Vte other diseases
Šibenik-Knin  74 (49.0) 18 (11.9) 11 (7.29)  4 (36.4)  7 (63.6)
Koprivnica-Križevci  40 (46.0) 10 (11.5)  6 (6.9)  4 (66.7)  2 (33.3)
Varaždin 122 (40.9) 39 (13.1) 38 (12.8) 16 (42.1) 22 (57.9)
Brod-Posavina  47 (37.0) 12 (9.5) 15 (11.8) 11 (73.3)  4 (26.7)
Total 283 (42.7) 79 (11.9) 70 (10.6) 35 (50.0) 35 (50.0)
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There were 59 (8.9%) VTE patients aged 45 or younger (Ta-
ble 4). Among them there were significantly more men 
than women (59.3% vs 40.7%, P = 0.011), significantly more 
cases of secondary than of idiopathic VTE (11.6% vs 5.3%, 
P = 0.005), and 22 cases (3.3% of all VTE patients) of idio-
pathic or recurrent VTE. There was no significant difference 
in VTE incidence between seasons or months of the year 
(data not shown).
Among all 663 VTE patients, 70 (10.6%) died, 50.0% of them 
with VTE as the main cause of death (Table 2). There was 
no difference in sex and no difference in VTE recurrence 
between patients who died and those who survived. Pa-
tients who died were significantly older than those who 
survived (median and range; 77 [26-90] vs 70 [13-97] years, 
P = 0.001). Among patients who died, significantly more 
patients had secondary (81.4%) than idiopathic (18.6%) 
VTE (P < 0.001).
When we compared the counties according to the type 
of VTE (DVT, PE, or both), Varaždin County had the highest 
percentage and Brod-Posavina County the lowest percent-
age of PE (P < 0.001). Furthermore, Brod-Posavina County 
had the highest percentage and Varaždin County the low-
est percentage of DVT (P < 0.001, Table 1). There were no 
significant differences between counties in age and sex of 
the patients, recurrence of VTE, percentage of idiopathic 
or secondary VTE, mortality, and cause of death. When we 
compared the counties according to the cause of second-
ary VTE, Brod-Posavina County had the highest percentage 
of trauma, surgery and immobilization (29.1%, P = 0.020), 
and Varaždin County the highest percentage of sepsis 
(9.4%, P < 0.001).
Varaždin County (1.694 per 1000 persons) and Šibenik-Knin 
County (1.381 per 1000 persons) had significantly higher 
incidence of VTE than Brod-Posavina County (0.8 per 1000 
taBLe 3. Causes of secondary newly diagnosed venous thromboembolism (Vte) in 4 Croatian counties in 2011
Secondary 
Causes of secondary Vte*
(N, % of secondary Vte in county and total)
County (N, % all Vte in county and total) cancer trauma, surgery, immobilization other†
Šibenik-Knin  77 (51.0)  39 (50.7)  23 (29.9)  28 (36.4)
Koprivnica-Križevci  47 (54.0)  20 (42.6)  24 (51.1)  19 (40.4)
Varaždin 176 (59.06)  68 (38.6)  61 (34.7)  87 (49.4)
Brod-Posavina  80 (63.0)  28 (22.1)  37 (46.3)  45 (56.3)
Total 380 (57.3) 155 (40.8) 145 (38.2) 179 (47.1)
*163 (42.9%) secondary Vte had >1 cause of secondary Vte.
†other causes of Vte included other diseases (eg, autoimmune diseases, inflammatory bowel diseases, neurological diseases with paralysis), sepsis, 
central venous catheter, drugs, pregnancy and puerperium, >6 h airplane flight.
taBLe 4. Patients aged 45 years or younger with newly diagnosed venous thromboembolism (Vte) in 4 Croatian counties in 2011
Younger ≤45 years (N, % of all Vte in county and total)
County total idiopathic recurrent idiopathic or recurrent
Šibenik-Knin 16 (10.6)  3 (1.9) 3 (1.9)  6 (3.9)
Koprivnica-Križevci  9 (10.3)  1 (1.15) 2 (2.3)  3 (3.45)
Varaždin 22 (7.4)  8 (2.7) 2 (0.7) 10 (3.4)
Brod-Posavina 12 (9.5)  3 (2.4) 1 (0.8)  3 (2.4)
Total 59 (8.9) 15 (2.3) 8 (1.2) 22 (3.3)
taBLe 5. incidence of venous thromboembolism (Vte) in 4 Croatian counties and estimated Vte incidence for the entire Croatia in 
2011
County
Number of inhabitants in 2011
(N, % of whole Croatia) Vte (N)
incidence of Vte 
per 1000 inhabitants
Šibenik-Knin* 109 375 (2.6) 151 1.381
Koprivnica-Križevci 115 584 (2.7)  87 0.753
Varaždin* 175 951 (4.1) 298 1.694
Brod-Posavina 158 575 (3.7) 127 0.800
Total 559 485 (13.1) 663 1.185
*Counties with higher incidence of Vte than other counties, P < 0.001.
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persons) and Koprivnica-Križevci County (0.753 per 1000 
persons; P < 0.001, Table 5). Estimated annual incidence of 
VTE in Croatia according to these 4 counties was 1.185 per 
1000 people.
DiSCuSSioN
Our study showed that the estimated incidence of VTE in 
Croatia in 2011 was 1.185 per 1000 people. This estimate, 
as well as the characteristics of VTE observed in this study, 
are similar to the findings of large international studies, al-
though there are also some differences. Age is an impor-
tant risk factor for VTE. Several studies showed that the 
incidence of VTE markedly increased with increasing age 
for both sexes, from fewer than 5 first-time VTE cases per 
100 000 per year among children younger than 15 years to 
450-600 cases per 100 000 per year among people older 
than 80 years (1,3,5). Indeed, in our study the majority of 
patients were older people (median age 71 years). In the 
past 50 years, the average age in Croatia increased by al-
most 10 years (from 32.5 in 1961 to 41.7 years in 2011), 
mostly due to a continuous decrease in fertility and in-
crease in life expectancy (22).
In our study, patients with PE or with both PE and DVT were 
older than patients with DVT alone. Other studies showed 
that the elderly more often had PE and had more serious 
VTE than younger patients, and that in their case massive 
PE was particularly life-threatening (23).
Although other studies mostly found no consistent differ-
ences in the incidence of VTE between men and women 
(5), our study found more female (56.3%) than male (43.7%) 
patients with newly diagnosed VTE. In Croatia there are 
more women (51.8%) than men (48.2%), but there are also 
different proportions of men and women in different age 
groups. For example, there are more men in younger age 
groups and more women in older age groups, starting 
with the age group 45-49 years (22). In our study, which 
mostly included elderly patients, female patients were sig-
nificantly older than male, but in the subgroup of patients 
aged 45 years or younger there were more male patients, 
reflecting the age-sex structure in Croatia.
In our study, recurrent VTE was diagnosed in 11.9% of pa-
tients. Recurrent VTE has been already recognized as a se-
rious problem. For example, in a prospective cohort study 
of 355 patients with DVT, Prandoni et al found recurrent 
VTE in 8.6% of cases after 6 months and in 30.3% of cas-
es after 8 years (12), while Heit et al reported recur-
rent VTE in 10.1% of cases after 6 months, in 12.9% after 1 
year, and in 30.4% after 10 years (18).
VTE is a multifactorial disease resulting from a complex inter-
action between different inherited (genetic) and acquired 
prothrombotic factors. Inherited thrombophilia is a predis-
position to thrombosis and exposes carriers to increased 
risks for VTE compared with non-carriers. Coen et al showed 
that the prevalence of FV Leiden and prothrombin G20210A 
mutations were higher in Croatian patients with VTE than in 
healthy subjects (24), and Jukic et al confirmed the associa-
tion of non-00 blood group genotypes with increased risk 
of VTE in Croatia (25). However, it is still a matter of intense 
debate under which circumstances comprehensive and ex-
pensive laboratory genetic testing for inherited thrombo-
philia is useful in clinical practice. Some authors suggest that 
thrombophilia screening should be considered in patients 
with VTE aged 45 years or younger, especially in those with 
idiopathic or recurrent VTE (26). Therefore, we analyzed the 
patients aged 45 years or younger and found 59 (8.9%) pa-
tients in that subgroup, with more cases of secondary than 
idiopathic VTE, and 22 of them (just 3.3% of all VTE patients) 
had idiopathic or recurrent VTE, representing possible can-
didates for genetic thrombophila testing.
In our study, there were more patients with secondary 
than with idiopathic VTE. In other studies, the proportion 
of patients with idiopathic VTE was between 26% and 47% 
of first-time cases, partly depending on the definition of id-
iopathic and secondary VTE used in the studies (5). In our 
study patients with idiopathic VTE were significantly older 
than those with secondary VTE, although both groups in-
cluded mostly elderly patients. There was no difference in 
disease recurrence or sex between patients with second-
ary and idiopathic VTE. The most frequent cause of second-
ary VTE was cancer (40.8% of secondary VTE), but 42.9% of 
cases with secondary VTE had more than one underlying 
condition associated with VTE.
Cancer is one of the strongest risk factors for VTE and, vice 
versa, VTE is a frequent complication of malignancy and 
may be the earliest manifestation of an occult cancer (27). 
The association of cancer and VTE is due to multiple fac-
tors: malignant cells can produce hypercoagulable state 
through multiple mechanisms, and the risk for VTE is fur-
ther increased by chemotherapy and other drugs for can-
cer treatment, the use of central venous catheters, surgery, 
and prolonged immobility (28,29). These patients require 
appropriate thromboprophylaxis and adequate long term 
anticoagulant treatment if VTE occurs (30).
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The second most frequent cause of secondary VTE in our 
study was trauma, surgery, and immobilization (38.2% 
of secondary VTE). It is known that surgery is related to a 
6-fold increased risk of VTE (7,9). The 9th edition of Anti-
thrombotic Therapy and Prevention of Thrombosis Guide-
lines of the American College of Chest Physicians state that 
the high incidence of postoperative VTE mandates that 
thromboprophylaxis should be considered in every surgi-
cal patient (31).
Although some studies showed a higher incidence of fatal 
PE during winter, others did not confirm this finding (5). 
Similarly, we did not find a significant difference in VTE in-
cidence either between seasons or between the months 
of the year.
In our study, 70 (10.6%) VTE patients died and in 50% of 
them VTE was the main cause of death. Patients who died 
and those who survived did not differ in sex and recur-
rence of VTE. The literature reports that the risk of dying 
is highest shortly after the VTE event, and that during the 
first year after the VTE it gradually approaches that in the 
general population (7). In our study, patients who died 
were significantly older than those who survived. Among 
patients who died, there were more patients with second-
ary than with idiopathic VTE. In patients with cancer, VTE 
is the second leading cause of death (32), and cancer was 
the most frequent underlying condition for secondary VTE 
in our study.
Diagnosis and treatment of VTE was performed in each 
hospital according to the standard clinical practice and lo-
cal policy. Therefore, the decision to perform Color Dop-
pler ultrasound analysis of peripheral veins to exclude DVT 
in patients with confirmed PE was made by the local physi-
cian depending of the clinical presentation and local pol-
icy, and was not part of this study. This might explain the 
finding that 219 (33.03%) patients had PE alone and just 36 
(5.43%) patients had confirmed both PE and DVT. Howev-
er, some studies also reported a small percentage (6%) of 
patients with both PE and DVT (7) and most clinical studies 
that did not include autopsy data described the incidence 
of clinically diagnosed DVT to be approximately twice that 
of PE (5), which is similar to our finding.
Varaždin County and Šibenik-Knin County had higher inci-
dence of VTE than Brod-Posavina County and Koprivnica-
Križevci County. These differences might be explained by 
the fact that Šibenik-Knin County has the oldest popula-
tion among the studied counties (average age 44.1 years) 
and is the second oldest county in Croatia after Lika-Senj 
County (22). On the other hand, General Hospital Varaždin, 
the only general hospital in Varaždin County, admits many 
chronically ill patients with immobility transferred from 
other regional special hospitals for chronic diseases or 
from rehabilitation centers, who are at a greater risk for VTE 
event (personal communication).
The estimated annual incidence of VTE in our study was 
1.185 per 1000 people (or 118.5 per 100 000 people), 
which is comparable to other literature data, where VTE in-
cidence rates varied from 1 to 2 per 1000 individuals per 
year (1-5,7,9). The epidemiology of VTE is always challeng-
ing: beside real differences, differences between studies 
may also arise from differences in study design, patients 
cohorts, and case definition (7).
This study has some limitations. First, the true incidence of 
VTE may have been underestimated for several reasons: 
we reviewed inpatient medical records and did not in-
clude VTE cases treated outside of the county general hos-
pitals (for example cases from nursing homes or sudden 
deaths from community). However, outpatient treatment 
of newly DVT and especially PE is extremely rare in Croatia. 
It is also likely that there were fatal and/or non diagnosed 
VTE events that were not inluded in this analysis. Another 
potential limitation is that assessment of associated condi-
tions and classification as idiopathic or secondary VTE were 
limited by contents of the medical record, and some data 
were missing for many patients such as smoking, obesity, 
diet, and family history for VTE.
Strengths of this study include involvement of 4 different 
counties from different parts of Croatia, representing 13.1% 
of Croatian population according to the national popula-
tion Census that was done in the same year as this study, 
thus representing the most accurate data. We believe that 
our study made a reliable estimate of the burden of VTE in 
Croatia, describing its characteristics and associated sub-
stantial mortality, which might help policy-makers to de-
velop strategies dealing with this major health problem.
However, further research is needed to estimate VTE in-
cidence in Croatia more accurately, to describe trends in 
incidence over time, and to implement optimal VTE pre-
vention and management. The literature data showed 
that the type, duration, and intensity of prophylaxis were 
frequently inappropriate and suboptimal (33-35). In our 
study, the most common risk factors for secondary VTE 
were cancer, trauma, surgery, and immobilization, 
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and many cases of secondary VTE had more than one un-
derlying condition. Since VTE is a preventable disease and 
effective prophylaxis is widely available – in addition to 
the development of new anticoagulants (36) – improved 
thromboprophylaxis in these settings might substantially 
lower the incidence and mortality of VTE.
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